Abstract
Paediatric migraine headache is a common condition for which there is no general consensus on the choice of prophylactic. Riboflavin has been considered as a potential prophylactic which is well tolerated. This review examines the current literature regarding the efficacy of riboflavin as a prophylactic. There have been mixed results from both retrospective studies as well as randomised controlled trials. Whilst the adverse effect profile is minimal compared to other migraine prophylactics, further well-designed studies with larger sample sizes and longer follow-up are required.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
